Compare BKSY & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKSY | SPRY |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | 340 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.7M | 860.0M |
| IPO Year | N/A | 2020 |
| Metric | BKSY | SPRY |
|---|---|---|
| Price | $25.83 | $8.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $28.50 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 05-07-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $26.22 | $90.76 |
| Revenue Next Year | $29.28 | $81.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.15 | $6.66 |
| 52 Week High | $33.20 | $18.63 |
| Indicator | BKSY | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 59.24 | 36.48 |
| Support Level | $16.51 | $8.05 |
| Resistance Level | $26.06 | $10.44 |
| Average True Range (ATR) | 2.23 | 0.47 |
| MACD | 0.33 | -0.02 |
| Stochastic Oscillator | 63.42 | 15.07 |
BlackSky Technology Inc is a provider of real-time geospatial intelligence. The company delivers on-demand, high-frequency imagery, monitoring, and analytics of some of the critical and strategic locations, economic assets, and events in the world. It designs, owns, and operates one of the industry's low earth orbit (LEO) small satellite constellations, optimized to capture imagery cost-efficiently where and when its customers need it. its Spectra AI software platform processes data from BlackSky's constellation and other third-party sensors to develop the critical insights and analytics that provide its customers with the actionable intelligence. Geographically, the company operates in North America, the Middle East, Asia, and Others.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.